Ashley E. Ross, MD, PhD, Texas Urology Specialists, Dallas, Texas, and M. Scott Lucia, University of Colorado, Denver, Aurora, Colorado, provide highlights of the Biomarkers for Localized Prostate Cancer session from the 18th Annual Future Directions in Urology Symposium.

 

 

Keywords: prostate cancer, biomarkers

 

ABOUT THE AUTHOR

+ posts

Ashley E. Ross, MD, PhD, is Executive Medical Director at Mary Crowley Cancer Research in Dallas, Texas. He also practices as a physician with Texas Oncology Practice Associates and Texas Urology Specialists. He was formerly an Associate Professor of Urology and Oncology at the Johns Hopkins School of Medicine where he led the Brady Urological Prostate Cancer Program and co-directed the Sidney Kimmel Cancer Center’s multidisciplinary prostate cancer clinic. Dr. Ross has been particularly interested in evaluating novel diagnostics and therapeutics and has led trials testing biomarkers for prostate cancer diagnosis, novel imaging modalities for staging, genomic markers to assess risk, and therapeutic trials for high-risk disease and low-volume metastatic disease. Dr. Ross is an Associate Editor of the “Journal of Prostate Cancer and Prostatic Diseases,” “Urology,” and “Annals of Surgical Oncology.” He is on the editorial board of the “British Journal of Urology” and “Urology Practice.” He has been recognized with numerous awards and honors, including the Johns Hopkins Clinical Scientist Award, the Department of Defense Prostate Cancer PTRA Award, the Patrick C. Walsh Prostate Cancer Research Award, and a Prostate Cancer Foundation Young Investigator Award.